We are live on ! Find out more

211 hedge funds and large institutions have $1.37B invested in Genmab in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 81 increasing their positions, 68 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 68

0% more call options, than puts

Call options by funds: $7.04M | Put options by funds: $7.01M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.08% less ownership

Funds ownership: 6.46% → 6.38% (-0.08%)

5% less capital inflows, than outflows

Capital inflows: $300M | Capital outflows: $314M

8% less funds holding

Funds holding: 229 → 211 (-18)

35% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 49

Holders
211
Holders Change
-18
Holders Change %
-7.86%
% of All Funds
3.69%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
32
Increased
81
Reduced
68
Closed
49
Calls
$7.04​M
Puts
$7.01​M
Net Calls
+$29​K
Net Calls Change
-⁠$101​K

GMAB Hedge Fund Activity: Q1 2021 in Review

211 of the 5,715 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2021, worth a combined $1.37B — down 21% from $1.72B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of GMAB and 32 opened new positions — a net loss of 17 holders — while 68 trimmed existing stakes and 81 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $57.8M. The largest seller was Jennison Associates, exiting entirely with an estimated $58.1M sold.

  • 211 institutional investors held Genmab (GMAB) as of Q1 2021, down from 229 in Q4 2020.
  • Funds reported $1.37B of Genmab stock for Q1 2021, down 21% quarter-over-quarter.
  • 32 funds opened new Genmab positions in Q1 2021 and 49 closed out, a net change of -17 holders.
  • The largest Genmab buyer in Q1 2021 was T. Rowe Price Associates, an estimated $57.8M added.
  • The largest Genmab seller in Q1 2021 was Jennison Associates, an estimated $58.1M sold.

Based on aggregated 13F filings for Q1 2021.